Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Healthcare Online Network.
New Clinic in Kitchener-Waterloo for Weight Loss, TRT, and Metabolic Health
Physician-led clinic expands medical weight loss, TRT, hair loss treatment and fatty liver care in Kitchener-Waterloo-Cambridge-Guelph. KITCHENER, ONTARIO, CANADA, October 20, 2025 /EINPresswire.com/ -- True North Metabolic today announced the...
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in...
Medi Hair Loss & Scalp Clinic Expands to Toronto, Bringing Advanced Hair Loss Solutions to the Greater Toronto Area
TORONTO, ONTARIO, CANADA, October 20, 2025 /EINPresswire.com/ -- Medi Hair Loss & Scalp Clinic, a trusted leader in hair loss and scalp health, has officially opened its doors in Toronto. This expansion provides professional support to...
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose...
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients...
NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025
Primary efficacy endpoint met in secondary refractory patients LYON, FRANCE, October 19, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biotechnology company pioneering novel therapies targeting Netrin-1 to overcome resistance to...
True North Metabolic Expands Physician-Led Weight Loss Care Across Kitchener-Waterloo
Medical weight loss and fatty liver services now available to Kitchener-Waterloo with access for Cambridge and Guelph patients. KITCHENER, ONTARIO, CANADA, October 20, 2025 /EINPresswire.com/ -- True North Metabolic announced the regional...
Medicare open enrollment kicks off in Montana – and plans are more expensive than ever
Gov't Institution
The Office of the Montana State Auditor, Commissioner of Securities and Insurance
·
October 17, 2025
Carly Graf | The Missoulian October 17, 2025 More than 260,000 Montanans will be notified this week that it’s time to enroll in a Medicare plan for next year. When they check out their options for re-upping the government-backed health insurance...
Owner: American Government
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for...
Clinical Trial Sponsor Selects Datatrak ePRO/eCOA and eConsent
Datatrak selected after evaluation of various eClinical systems because it seamlessly integrates all key eClinical functions on one dashboard with one login. Datatrak International (OTCMKTS:DTRK) AUSTIN, TX, UNITED STATES, October 17, 2025...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median...
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors...
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 continues to demonstrate a favorable safety and tolerability profile Registrational studies planned to start in mid-2026 Company to host an HNSCC KOL...
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor...
AHA expresses concerns on potential tariffs for PPE, other medical goods
The AHA urged the Department of Commerce Oct. 17 to take a balanced approach to ensuring dependable and affordable access to personal protective equipment, medical consumables and medical equipment as it considers future tariff and trade policy....
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and...
Cleanfarms Brings Unwanted Pesticides & Old Livestock Medications Collection to Newfoundland, and Adds Recycling for Small Containers This October
ETOBICOKE, Ontario, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cleanfarms is bringing its unwanted pesticide and old livestock/equine medication (UPLM) collection program to Newfoundland from October 21 to 24, with events scheduled in Foxtrap, Lethbridge,...
Blue Goat Cyber to Showcase Healthcare and Medical Device Cybersecurity Solutions at HLTH 2025 in Las Vegas
Protecting patients through secure, compliant healthcare technology — Blue Goat Cyber joins HLTH 2025 at Booth #951-3. LAS VEGAS, NV, UNITED STATES, October 17, 2025 /EINPresswire.com/ -- Blue Goat Cyber, a leader in healthcare cybersecurity,...
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages RCI Hospitality Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – RICK
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 and September 16, 2025, both dates...
RCI Hospitality Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 20, 2025 to Discuss Your Rights – RICK
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RCI Hospitality Holdings, Inc. ("RCI Hospitality Holdings, Inc." or the "Company") (NASDAQ: RICK) of a class action securities lawsuit. CLASS DEFINITION: The...